WO2001074357A1 - Hydrophilic molecular disperse solutions of carvedilol - Google Patents
Hydrophilic molecular disperse solutions of carvedilol Download PDFInfo
- Publication number
- WO2001074357A1 WO2001074357A1 PCT/EP2001/003502 EP0103502W WO0174357A1 WO 2001074357 A1 WO2001074357 A1 WO 2001074357A1 EP 0103502 W EP0103502 W EP 0103502W WO 0174357 A1 WO0174357 A1 WO 0174357A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carvedilol
- composition according
- pharmaceutically acceptable
- solid
- active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001256227A AU2001256227B2 (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
AT01929462T ATE450257T1 (en) | 2000-04-03 | 2001-03-28 | HYDROPHILIC MOLECULAR DISPERSE SOLUTIONS OF CARVEDILOL |
KR10-2002-7013230A KR100478793B1 (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
HU0300342A HUP0300342A3 (en) | 2000-04-03 | 2001-03-28 | Compositions containing hydrophilic molecular disperse solutions of carvedilol, process for their preparation and their use |
BR0109779-2A BR0109779A (en) | 2000-04-03 | 2001-03-28 | Carvedilol hydrophilic dispersed molecular solutions |
JP2001572101A JP2003528915A (en) | 2000-04-03 | 2001-03-28 | Carvedilol hydrophilic molecule dispersion |
EP01929462A EP1272179B1 (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
CA002401910A CA2401910C (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
IL15164201A IL151642A0 (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
AU5622701A AU5622701A (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
NZ521232A NZ521232A (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
DE60140662T DE60140662D1 (en) | 2000-04-03 | 2001-03-28 | HYDROPHIL MOLECULAR DISPERSE SOLUTIONS OF CARVEDILOL |
PL01358103A PL358103A1 (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
MXPA02009725A MXPA02009725A (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol. |
HRP20020777 HRP20020777A2 (en) | 2000-04-03 | 2002-09-26 | Hydrophilic molecular disperse solutions of carvedilol |
NO20024733A NO20024733D0 (en) | 2000-04-03 | 2002-10-02 | Hydrophilic molecular dispersion solutions of carvedilol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00107093 | 2000-04-03 | ||
EP00107093.7 | 2000-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001074357A1 true WO2001074357A1 (en) | 2001-10-11 |
Family
ID=8168348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/003502 WO2001074357A1 (en) | 2000-04-03 | 2001-03-28 | Hydrophilic molecular disperse solutions of carvedilol |
Country Status (24)
Country | Link |
---|---|
US (3) | US20010036959A1 (en) |
EP (1) | EP1272179B1 (en) |
JP (1) | JP2003528915A (en) |
KR (1) | KR100478793B1 (en) |
CN (1) | CN1189171C (en) |
AR (1) | AR029825A1 (en) |
AT (1) | ATE450257T1 (en) |
AU (2) | AU2001256227B2 (en) |
BR (1) | BR0109779A (en) |
CA (1) | CA2401910C (en) |
CZ (1) | CZ20023625A3 (en) |
DE (1) | DE60140662D1 (en) |
HR (1) | HRP20020777A2 (en) |
HU (1) | HUP0300342A3 (en) |
IL (1) | IL151642A0 (en) |
MA (1) | MA26888A1 (en) |
MX (1) | MXPA02009725A (en) |
NO (1) | NO20024733D0 (en) |
NZ (1) | NZ521232A (en) |
PL (1) | PL358103A1 (en) |
RU (1) | RU2248204C2 (en) |
WO (1) | WO2001074357A1 (en) |
YU (1) | YU72602A (en) |
ZA (1) | ZA200207304B (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024426A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Controlled release solid dispersions |
WO2003024429A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
WO2004041252A1 (en) * | 2002-11-08 | 2004-05-21 | Egalet A/S | Controlled release carvedilol compositions |
WO2004084869A1 (en) * | 2003-03-26 | 2004-10-07 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
WO2004084868A1 (en) * | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
JP2005517041A (en) * | 2002-02-14 | 2005-06-09 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Oral solid solution formulation of poorly water-soluble active substance |
JP2005533823A (en) * | 2002-06-27 | 2005-11-10 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Carvedilol phosphate and / or solvates thereof, corresponding compositions and / or methods of treatment |
WO2008068731A1 (en) * | 2006-12-06 | 2008-06-12 | Biovail Laboratories International S.R.L. | Extended release formulations of carvedilol |
US7423004B2 (en) | 2003-01-31 | 2008-09-09 | Smithkline Beecham Corporation | Solid dispersion compositions |
EP2155171A1 (en) * | 2007-04-27 | 2010-02-24 | Libbs Farmacêutica Ltda | Osmotic form for controlled release of active principles |
US7883722B2 (en) | 1998-04-03 | 2011-02-08 | Egalet Ltd. | Controlled release composition |
JP2011251972A (en) * | 2003-08-29 | 2011-12-15 | Veloxis Pharmaceuticals As | Pharmaceutical composition comprising tacrolimus |
WO2011154009A1 (en) * | 2010-06-10 | 2011-12-15 | Lifecycle Pharma A/S | Composition comprising an active principle in an amorphous form and a porous adsorbent material |
US8367112B2 (en) | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
US8609143B2 (en) | 2001-09-21 | 2013-12-17 | Egalet Ltd. | Morphine polymer release system |
US8974823B2 (en) | 2003-12-31 | 2015-03-10 | Bend Research, Inc. | Solid compositions of low-solubility drugs and poloxamers |
US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9023394B2 (en) | 2009-06-24 | 2015-05-05 | Egalet Ltd. | Formulations and methods for the controlled release of active drug substances |
US9044402B2 (en) | 2012-07-06 | 2015-06-02 | Egalet Ltd. | Abuse-deterrent pharmaceutical compositions for controlled release |
US9642809B2 (en) | 2007-06-04 | 2017-05-09 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
KR20170093589A (en) | 2016-02-05 | 2017-08-16 | 삼진제약주식회사 | Carvedilol immediate release formulation having improved madescent |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005507899A (en) * | 2001-09-28 | 2005-03-24 | エフ.ホフマン−ラ ロシュ アーゲー | Pseudopolymorphic form of carvedilol |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
EP1499310A4 (en) * | 2002-04-30 | 2005-12-07 | Sb Pharmco Inc | Carvedilol monocitrate monohydrate |
WO2003092625A2 (en) * | 2002-05-03 | 2003-11-13 | Smithkline Beecham Pharmco Puerto Rico, Inc. | Carvedilol formulations |
WO2004002472A1 (en) * | 2002-06-27 | 2004-01-08 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydrobromide |
BRPI0412329A (en) * | 2003-07-09 | 2006-09-05 | Chong Kun Dang Pharm Corp | tacrolimus solid dispersion and method of processing the same |
JP4903568B2 (en) * | 2003-08-29 | 2012-03-28 | ベロクシス ファーマシューティカルズ エー/エス | Solid dispersion containing tacrolimus |
EP1686967A4 (en) * | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
EP1686986A4 (en) * | 2003-11-25 | 2009-05-27 | Sb Pharmco Inc | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
JP5072364B2 (en) * | 2003-11-25 | 2012-11-14 | スミスクライン ビーチャム (コーク) リミテッド | Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method |
JP2007517015A (en) * | 2003-12-31 | 2007-06-28 | ファイザー・プロダクツ・インク | Stabilized pharmaceutical solid composition of low solubility drug, poloxamer and stabilizing polymer |
EP1895989A2 (en) * | 2005-06-03 | 2008-03-12 | Egalet A/S | A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008086804A2 (en) * | 2007-01-16 | 2008-07-24 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
EP2259801B1 (en) | 2008-03-04 | 2012-01-04 | Lupin Limited | Stable pharmaceutical compositions of carvedilol |
ES2330404B1 (en) * | 2008-05-19 | 2010-09-22 | Universidad De Barcelona | WATER SOLUTION FOR THE PRESERVATION OF FABRICS AND ORGANS. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023022A1 (en) * | 1992-05-19 | 1993-11-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
DE19809242A1 (en) * | 1998-03-05 | 1999-09-09 | Basf Ag | Process for the production of solid, spherical shaped articles containing pharmaceutical active substances in a binder matrix |
DE19816036A1 (en) * | 1998-04-09 | 1999-10-14 | Roche Diagnostics Gmbh | Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2815926A1 (en) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | NEW CARBAZOLYL- (4) -OXY-PROPANOLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
DE3319027A1 (en) * | 1983-05-26 | 1984-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBAZOL DERIVATIVES, NEW R- AND S-CARBAZOL DERIVATIVES, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US5258185A (en) * | 1989-08-23 | 1993-11-02 | Bauer Kurt H | Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use |
US5760069A (en) * | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
DE19637082A1 (en) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Rapidly disintegrating pellets |
DE69826113T2 (en) * | 1997-03-11 | 2005-01-20 | Arakis Ltd., Saffron Walden | R AND S-ENANTIOMER SEPARATED DOSAGE FORMS |
US6852337B2 (en) * | 1998-04-09 | 2005-02-08 | Roche Diagnostics Gmbh | Carvedilol-galenics |
US6664284B2 (en) * | 1998-07-23 | 2003-12-16 | Roche Diagnostics Gmbh | Stabilized carvedilol injection solution |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6710184B2 (en) * | 2002-01-15 | 2004-03-23 | Teva Pharmaceutical Industries Ltd. | Crystalline solids of carvedilol and processes for their preparation |
-
2001
- 2001-03-26 US US09/817,308 patent/US20010036959A1/en not_active Abandoned
- 2001-03-28 WO PCT/EP2001/003502 patent/WO2001074357A1/en not_active Application Discontinuation
- 2001-03-28 CN CNB018074278A patent/CN1189171C/en not_active Expired - Fee Related
- 2001-03-28 PL PL01358103A patent/PL358103A1/en not_active Application Discontinuation
- 2001-03-28 BR BR0109779-2A patent/BR0109779A/en not_active Application Discontinuation
- 2001-03-28 AT AT01929462T patent/ATE450257T1/en not_active IP Right Cessation
- 2001-03-28 YU YU72602A patent/YU72602A/en unknown
- 2001-03-28 JP JP2001572101A patent/JP2003528915A/en not_active Ceased
- 2001-03-28 RU RU2002129571/15A patent/RU2248204C2/en not_active IP Right Cessation
- 2001-03-28 EP EP01929462A patent/EP1272179B1/en not_active Revoked
- 2001-03-28 AU AU2001256227A patent/AU2001256227B2/en not_active Ceased
- 2001-03-28 DE DE60140662T patent/DE60140662D1/en not_active Expired - Fee Related
- 2001-03-28 CA CA002401910A patent/CA2401910C/en not_active Expired - Fee Related
- 2001-03-28 IL IL15164201A patent/IL151642A0/en unknown
- 2001-03-28 HU HU0300342A patent/HUP0300342A3/en unknown
- 2001-03-28 MX MXPA02009725A patent/MXPA02009725A/en active IP Right Grant
- 2001-03-28 CZ CZ20023625A patent/CZ20023625A3/en unknown
- 2001-03-28 KR KR10-2002-7013230A patent/KR100478793B1/en not_active IP Right Cessation
- 2001-03-28 NZ NZ521232A patent/NZ521232A/en unknown
- 2001-03-28 AU AU5622701A patent/AU5622701A/en active Pending
- 2001-03-30 AR ARP010101538A patent/AR029825A1/en not_active Application Discontinuation
-
2002
- 2002-08-08 US US10/214,697 patent/US20030004205A1/en not_active Abandoned
- 2002-09-11 ZA ZA200207304A patent/ZA200207304B/en unknown
- 2002-09-26 HR HRP20020777 patent/HRP20020777A2/en not_active Application Discontinuation
- 2002-10-01 MA MA26845A patent/MA26888A1/en unknown
- 2002-10-02 NO NO20024733A patent/NO20024733D0/en unknown
-
2005
- 2005-08-16 US US11/204,614 patent/US20050271721A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023022A1 (en) * | 1992-05-19 | 1993-11-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
DE19809242A1 (en) * | 1998-03-05 | 1999-09-09 | Basf Ag | Process for the production of solid, spherical shaped articles containing pharmaceutical active substances in a binder matrix |
DE19816036A1 (en) * | 1998-04-09 | 1999-10-14 | Roche Diagnostics Gmbh | Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7883722B2 (en) | 1998-04-03 | 2011-02-08 | Egalet Ltd. | Controlled release composition |
EP1929998A3 (en) * | 2001-09-21 | 2008-11-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
WO2003024429A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
WO2003024426A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Controlled release solid dispersions |
US9707179B2 (en) | 2001-09-21 | 2017-07-18 | Egalet Ltd. | Opioid polymer release system |
US9694080B2 (en) | 2001-09-21 | 2017-07-04 | Egalet Ltd. | Polymer release system |
US8617605B2 (en) | 2001-09-21 | 2013-12-31 | Egalet Ltd. | Polymer release system |
US8609143B2 (en) | 2001-09-21 | 2013-12-17 | Egalet Ltd. | Morphine polymer release system |
JP2005517041A (en) * | 2002-02-14 | 2005-06-09 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Oral solid solution formulation of poorly water-soluble active substance |
JP2005533823A (en) * | 2002-06-27 | 2005-11-10 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Carvedilol phosphate and / or solvates thereof, corresponding compositions and / or methods of treatment |
JP2013241450A (en) * | 2002-06-27 | 2013-12-05 | Smithkline Beecham (Cork) Ltd | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or treatment methods |
JP2011088917A (en) * | 2002-06-27 | 2011-05-06 | Smithkline Beecham (Cork) Ltd | Carvedilol phosphate salt and/or solvate thereof, corresponding composition, and/or method of treatment |
US8449914B2 (en) | 2002-11-08 | 2013-05-28 | Egalet Ltd. | Controlled release carvedilol compositions |
WO2004041252A1 (en) * | 2002-11-08 | 2004-05-21 | Egalet A/S | Controlled release carvedilol compositions |
US7423004B2 (en) | 2003-01-31 | 2008-09-09 | Smithkline Beecham Corporation | Solid dispersion compositions |
US8298581B2 (en) | 2003-03-26 | 2012-10-30 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
US9884029B2 (en) | 2003-03-26 | 2018-02-06 | Egalet Ltd. | Morphine controlled release system |
US9375428B2 (en) | 2003-03-26 | 2016-06-28 | Egalet Ltd. | Morphine controlled release system |
WO2004084869A1 (en) * | 2003-03-26 | 2004-10-07 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
WO2004084868A1 (en) * | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
EP2186510A2 (en) | 2003-03-26 | 2010-05-19 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
JP2006521301A (en) * | 2003-03-26 | 2006-09-21 | エガレット エイ/エス | Matrix composition for controlled delivery of drug substance |
EP2186510A3 (en) * | 2003-03-26 | 2010-06-09 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
EP1974726A3 (en) * | 2003-03-26 | 2008-11-05 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
US10548880B2 (en) | 2003-08-29 | 2020-02-04 | Veloxis Pharmaceuticals A/S | Solid dispersions comprising tacrolimus |
US11077096B2 (en) | 2003-08-29 | 2021-08-03 | Veloxis Pharmaceuticals Inc. | Modified release compositions comprising tacrolimus |
US9757362B2 (en) | 2003-08-29 | 2017-09-12 | Veloxis Pharmaceuticals A/S | Modified release compositions comprising tacrolimus |
JP2011251972A (en) * | 2003-08-29 | 2011-12-15 | Veloxis Pharmaceuticals As | Pharmaceutical composition comprising tacrolimus |
US11129815B2 (en) | 2003-08-29 | 2021-09-28 | Veloxis Pharmaceuticals Inc. | Solid dispersions comprising tacrolimus |
US8974823B2 (en) | 2003-12-31 | 2015-03-10 | Bend Research, Inc. | Solid compositions of low-solubility drugs and poloxamers |
US8367112B2 (en) | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
WO2008068731A1 (en) * | 2006-12-06 | 2008-06-12 | Biovail Laboratories International S.R.L. | Extended release formulations of carvedilol |
EP2155171A1 (en) * | 2007-04-27 | 2010-02-24 | Libbs Farmacêutica Ltda | Osmotic form for controlled release of active principles |
EP2155171A4 (en) * | 2007-04-27 | 2011-08-10 | Libbs Farmaceutica Ltda | Osmotic form for controlled release of active principles |
US9642809B2 (en) | 2007-06-04 | 2017-05-09 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
US9358295B2 (en) | 2009-02-06 | 2016-06-07 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9023394B2 (en) | 2009-06-24 | 2015-05-05 | Egalet Ltd. | Formulations and methods for the controlled release of active drug substances |
WO2011154009A1 (en) * | 2010-06-10 | 2011-12-15 | Lifecycle Pharma A/S | Composition comprising an active principle in an amorphous form and a porous adsorbent material |
US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
US9044402B2 (en) | 2012-07-06 | 2015-06-02 | Egalet Ltd. | Abuse-deterrent pharmaceutical compositions for controlled release |
KR20170093589A (en) | 2016-02-05 | 2017-08-16 | 삼진제약주식회사 | Carvedilol immediate release formulation having improved madescent |
Also Published As
Publication number | Publication date |
---|---|
MXPA02009725A (en) | 2003-03-27 |
RU2248204C2 (en) | 2005-03-20 |
ATE450257T1 (en) | 2009-12-15 |
ZA200207304B (en) | 2003-12-11 |
US20050271721A1 (en) | 2005-12-08 |
DE60140662D1 (en) | 2010-01-14 |
EP1272179A1 (en) | 2003-01-08 |
JP2003528915A (en) | 2003-09-30 |
CN1189171C (en) | 2005-02-16 |
AR029825A1 (en) | 2003-07-16 |
CN1420771A (en) | 2003-05-28 |
YU72602A (en) | 2005-03-15 |
CZ20023625A3 (en) | 2003-04-16 |
US20030004205A1 (en) | 2003-01-02 |
HUP0300342A2 (en) | 2003-06-28 |
IL151642A0 (en) | 2003-04-10 |
EP1272179B1 (en) | 2009-12-02 |
CA2401910C (en) | 2008-04-15 |
BR0109779A (en) | 2003-01-21 |
NZ521232A (en) | 2004-05-28 |
US20010036959A1 (en) | 2001-11-01 |
PL358103A1 (en) | 2004-08-09 |
KR20030019339A (en) | 2003-03-06 |
HUP0300342A3 (en) | 2005-07-28 |
NO20024733L (en) | 2002-10-02 |
AU5622701A (en) | 2001-10-15 |
AU2001256227B2 (en) | 2005-09-01 |
MA26888A1 (en) | 2004-12-20 |
NO20024733D0 (en) | 2002-10-02 |
KR100478793B1 (en) | 2005-03-24 |
RU2002129571A (en) | 2004-03-27 |
CA2401910A1 (en) | 2001-10-11 |
HRP20020777A2 (en) | 2004-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2401910C (en) | Hydrophilic molecular disperse solutions of carvedilol | |
AU2001256227A1 (en) | Hydrophilic molecular disperse solutions of carvedilol | |
EP1272180B1 (en) | Concentrated solutions of carvedilol | |
US20060148878A1 (en) | Pseudopolymorphic forms of carvedilol | |
JP2009510138A (en) | Solid pharmaceutical dosage form that can be administered orally and has a rapid release of the active ingredient | |
JP2020513023A (en) | Amorphous Form and Solid Dispersion of Lumateperone p-Tosylate | |
JP5840684B2 (en) | Dronedarone solid dispersant and process for producing the same | |
TWI299994B (en) | Anti-allergic agent pharmaceutical composition and production method therefor | |
EP3192502A1 (en) | Pharmaceutical composition of selexipag | |
AU2002338726A1 (en) | Pseudopolymorphic forms of carvedilol | |
CN116133646A (en) | Pratinib pharmaceutical composition | |
WO2016169534A1 (en) | Solid forms of amorphous empagliflozin | |
CN116685308A (en) | Amorphous solid dispersion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-726/02 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2401910 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 151642 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 521232 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/07304 Country of ref document: ZA Ref document number: 200207304 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001256227 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001929462 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018074278 Country of ref document: CN Ref document number: P20020777A Country of ref document: HR |
|
ENP | Entry into the national phase |
Ref document number: 2001 572101 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 02088279 Country of ref document: CO Ref document number: IN/PCT/2002/1587/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/009725 Country of ref document: MX Ref document number: 1020027013230 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-3625 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002129571 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2001929462 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027013230 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-3625 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 521232 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 521232 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020027013230 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001256227 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2002-3625 Country of ref document: CZ |